Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sten Stovall

London, UK
Sten Stovall is a London-based editor and writer with 40 years of experience in the field of journalism, including more than 20 years with Reuters and eight years with The Wall Street Journal/Dow Jones Newswires. He also has wide radio and television reporting experience and a solid network of contacts in the biopharma world. Sten is part of our team of specialist reporters, generating insightful features and analysis about R&D, product development, regulatory issues and industry trends for publications such as "The Pink Sheet", Scrip and IN VIVO.
Advertisement
Set Alert for Articles By Sten Stovall

Latest From Sten Stovall

Roche CEO: Novel But Costly Gene Therapies Justify New Payment Models

Roche CEO Severin Schwan says the process of paying for hugely expensive gene therapies that can cure diseases needs revamping.

Gene Therapy Pricing Strategies

Gelesis's Plenity Obesity Product Earns De Novo For Wide BMI Range

PureTech's affiliate Gelesis has received US FDA de novo clearance for its Plenity capsule to treat overweight-obese adults, and plans to launch it commercially in the second half.

Approvals Research & Development

Cassiopea Hails Breezula's 'Good Hair Day' And Plans FDA Talks On Phase III

Italy-based Cassiopea says “very positive results” from Breezula's 12-month Phase II alopecia trial support progressing  it to Phase III, particularly given the clean safety profile.

Clinical Trials Companies

Gelesis's Obesity Product FDA Acceptance Gives Boost To PureTech's Portfolio


PureTech's affiliate Gelesis has received FDA clearance for its Plenity capsule to treat overweight-obese adults, and plans to launch it commercially in the second half. 
Approvals Metabolic Disorders

Product Sales, Pipeline & Biosimilar Timelines Key Themes For Roche 1Q

Investors during Roche’s first-quarter update Wednesday will be looking for clues on looming biosimilar competition and timelines for the emergence of promising pipeline assets.

Commercial Companies

Novartis’s NASH Chief: Our Strategy Is Combos With Tropifexor As ‘Backbone’

Novartis's broad but early-stage NASH pipeline will use FXR agonist tropifexor as its keystone for developing combination therapies with outside partners.

Research and Development Strategies Liver & Hepatic
See All
Advertisement
UsernamePublicRestriction

Register